Fragile X targeted pharmacotherapy: lessons learned and future directions. by Erickson, Craig A et al.
UC Davis
UC Davis Previously Published Works
Title
Fragile X targeted pharmacotherapy: lessons learned and future directions.
Permalink
https://escholarship.org/uc/item/6h13d66k
Journal
Journal of neurodevelopmental disorders, 9(1)
ISSN
1866-1947
Authors
Erickson, Craig A
Davenport, Matthew H
Schaefer, Tori L
et al.
Publication Date
2017
DOI
10.1186/s11689-017-9186-9
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
REVIEW Open Access
Fragile X targeted pharmacotherapy:
lessons learned and future directions
Craig A. Erickson1,2*, Matthew H. Davenport1,3, Tori L. Schaefer1, Logan K. Wink1,2, Ernest V. Pedapati1,2,
John A. Sweeney2, Sarah E. Fitzpatrick1, W. Ted Brown10, Dejan Budimirovic11,12, Randi J. Hagerman4,5,
David Hessl4,6, Walter E. Kaufmann7,8 and Elizabeth Berry-Kravis9
Abstract
Our understanding of fragile X syndrome (FXS) pathophysiology continues to improve and numerous potential
drug targets have been identified. Yet, current prescribing practices are only symptom-based in order to manage
difficult behaviors, as no drug to date is approved for the treatment of FXS. Drugs impacting a diversity of targets
in the brain have been studied in recent FXS-specific clinical trials. While many drugs have focused on regulation
of enhanced glutamatergic or deficient GABAergic neurotransmission, compounds studied have not been limited
to these mechanisms. As a single-gene disorder, it was thought that FXS would have consistent drug targets that
could be modulated with pharmacotherapy and lead to significant improvement. Unfortunately, despite promising
results in FXS animal models, translational drug treatment development in FXS has largely failed. Future success in this
field will depend on learning from past challenges to improve clinical trial design, choose appropriate outcome
measures and age range choices, and find readily modulated drug targets. Even with many negative placebo-controlled
study results, the field continues to move forward exploring both the new mechanistic drug approaches combined with
ways to improve trial execution. This review summarizes the known phenotype and pathophysiology of FXS and past
clinical trial rationale and results, and discusses current challenges facing the field and lessons from which to learn for
future treatment development efforts.
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Background
Fragile X syndrome (FXS) is the most common single
gene disorder associated with autism spectrum disorder
(ASD) and most common inherited cause of develop-
mental disability. FXS impacts 1 in 4000 males and 1 in
4000–6000 females worldwide [1–5]. FXS results from
silencing of the fragile X mental retardation gene
(FMR1) on the long arm of the X chromosome. Silen-
cing of FMR1 is nearly always caused by hypermethyla-
tion of a cytosine guanine guanine (CGG) trinucleotide
repeat expansion (≥200 repeats is termed the “full muta-
tion” and causes FXS) in the 5′ untranslated region
(UTR) of the FMR1 gene [6, 7]. FMR1 inactivation
results in absent or deficient production of fragile X
mental retardation protein (FMRP). In all cases, full mu-
tation FXS results from maternal transmission, in which
a mother transmits her full mutation allele or her pre-
mutation (carrier) allele (55–200 CGG repeats; typical
population has fewer than 45 repeats), which undergoes
CGG repeat expansion when it transmits to the next
generation. As an X-linked disorder, FXS universally im-
pacts affected males, while its presentation is variable in
females due to random X inactivation patterns. In FXS,
excessive and poorly regulated protein synthesis is
pathogenic, which then manifests in myriad ways [8].
Developmental disability, most commonly in the moder-
ate to severe range of cognitive impairment, is universal
in males. Common physical and medical features in FXS
include increased risk for chronic otitis media, esotropia,
hyperextensible joints, high arched palate, low muscle
tone, seizures, and macroorchidism with puberty [9, 10].
The neurobehavioral presentation of FXS includes risk
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for sleep disturbance, aggression, attention deficit hyper-
activity disorder (ADHD) symptoms, significant anxiety,
sensory hypersensitivities, self-injury, and physical ag-
gression [4, 11, 12]. There is a significant overlap be-
tween FXS and ASD, with up to 2 in 3 males with FXS
having features consistent with the broader ASD pheno-
type [3, 5, 13, 14].
FMRP is widely expressed in humans. In the human
brain, FMRP is expressed in mature astrocytes and in the
dendrites, spines, and soma of mature neurons [15–19].
FMRP is involved in translational repression and thought
to selectively bind to about 4% of all mRNAs translated in
the brain [17–20], but the impact of deficient FMRP is
complex, including an expected increase in translation of
many RNA targets. However, protein expression of other
mRNA targets of FMRP may be unchanged or even re-
duced in FXS, thus pointing to poorly understood com-
pensatory or other regulatory mechanisms [21].
The loss of FMRP results in a number of brain effects at
macroscopic, microscopic, and molecular levels. Neuroim-
aging abnormalities noted in youth with FXS include lar-
ger temporal lobe white matter, cerebellar gray matter,
and caudate nucleus with smaller amygdala compared to
controls [22]. At a microscopic level, dendritic abnormal-
ities associated with deficient FMRP include increased
spine density with longer, spindly, and immature morph-
ology reported in postmortem human and Fmr1 knockout
(KO) mouse brain tissue [23–25]. Molecular and dendritic
abnormalities may result in functional brain deficits, in-
cluding disruption of synaptic plasticity with enhanced
long-term depression (LTD) [26–29] and brain region-
specific long-term potentiation (LTP) deficits [30–33].
Not surprisingly, given the large number of proteins for
which production is altered by FMRP deficiency, many
molecular signaling cascades involved in synaptic plas-
ticity, learning, and memory are known to function
abnormally in the Fmr1 KO mouse and in human cells.
Some of these likely dysregulated molecular systems in-
clude phosphoinositide 3-kinase (PI3K) [34–36], extracel-
lular signal-related kinase (ERK1/2) [37–39], matrix
metalloproteinase 9 (MMP-9) [40, 41], endocannabinoid
[42–45], brain-derived neurotrophic factor (BDNF) [46,
47], and mammalian target of rapamycin (mTOR) [48–
50]. The broad array of potential molecular targets for
pharmacotherapy in FXS is a testament to the broad
impact of deficient FMRP, and thus the potential chal-
lenge of targeting multiple aspects of molecular dys-
regulation simultaneously [42–45].
As a single gene disorder with increasing efforts to de-
fine and then address the neurobiological underpinning
of the disorder, FXS has been the subject of a recent
wave of targeted treatment development efforts. Despite
significant hopes for translational treatment success, to
date no drug has met approval for use specifically in
FXS. Given this, the pharmacotherapy of FXS in clinic
continues to be limited to symptomatic treatments of
comorbid abnormal behaviors, employing medications
such as selective serotonin reuptake inhibitors (SSRIs),
stimulants, and second-generation (atypical) antipsy-
chotics [51]. We will focus on efforts to develop FXS-
specific pharmacotherapy, including the translational
basis for various treatment hypotheses, focused on
results of human studies. Finally, we will look in detail at
potential reasons for study failure providing future direc-
tions for consideration to address such challenges.
Modulation of glutamate and GABA
neurotransmission
Many of the recent targeted clinical trials in FXS have ad-
dressed a potential excitatory/inhibitory neurotransmis-
sion imbalance associated with the disorder (Table 1). In
the FXS brain, there is believed to be an excess of excita-
tory, glutamatergic signaling coupled with deficiencies in
inhibitory, γ-Aminobutyric acid (GABA)-ergic signaling
[52]. Several recent human trials in FXS have focused on
reducing excitatory glutamatergic neurotransmission. Spe-
cific glutamatergic effects probed in humans with FXS have
included antagonism of group I metabotropic glutamate re-
ceptors (mGluRs), particularly mGluR5 (ClinicalTrials.gov
Identifiers: NCT01253629, NCT01357239, NCT01517698,
NCT01015430, NCT01750957), the N-methyl-D-aspartate
(NMDA) receptor, stimulation of GABA(B) receptors
(NCT01325220, NCT00788073, NCT01282268), and
modulation of the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid glutamate receptor (AMPAR;
NCT00054730).
The mGluR theory of FXS pathophysiology has driven
the wave of glutamatergic modulator studies in FXS.
The mGluR theory postulates that in FXS, excessive sig-
naling through mGluRs contributes to behavioral, elec-
trophysiological, and molecular dysfunction associated
with the disorder [8]. The mGluR theory brought to-
gether several key findings, including observations that
FMRP represses protein translation at the synapse [53],
synaptic protein synthesis can be triggered by activation
of mGluRs [16], FMRP deficit leads to increased down-
stream effects of mGluR signaling [26, 54], and many of
these downstream effects are dependent on mRNA
translation at the synapse [55–58]. The mGluR theory
has been extensively corroborated in FXS preclinical re-
search using 2-methyl-6(phenylethynyl)pyridine (MPEP),
a selective mGluR5 antagonist neurotoxic to humans.
This work has included many studies of treatment of the
Fmr1 KO mouse with selective mGluR5 antagonists,
demonstrating rescue of aberrant AMPAR expression,
behavioral deficits, electrophysiological abnormalities,
protein expression dysregulation, and altered dendritic
spine morphology [29, 59–61]. Further corroboration of
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the mGluR theory has come from genetic knockdown
studies in the Fmr1 KO mice, in which reduction in
mGluR5 expression normalized protein synthesis, den-
dritic spine deficits, and aspects of aberrant behavior
[62], although a second study using the same model
found very few behavioral improvements [63].
Within investigation of excitory/inhibitory imbalance,
enhanced glutamatergic signaling has received the most
attention in FXS, but GABAergic deficits have been in-
creasingly recognized as contributing to the hypothe-
sized excitatory/inhibitory imbalance. In the Fmr1 KO
mouse, deficits in GABAergic signaling occur in a variety
of brain regions including the hippocampus, striatum,
amygdala, and somatosensory cortex [64–67]. Most
commonly, preclinical findings of GABAergic deficits
have centered on reduction in GABA(A) subunit recep-
tor expression, although GABA synthesis and release
may also be affected [64]. In preclinical treatment study
in the mouse and fly model of FXS, positive modulation
of GABA(A) receptors can rescue some behavioral and
neurophysiological alterations [68, 69]. GABA(B) activa-
tors also rescued an array of phenotypes including spine
morphology, audiogenic seizures, and cellular abnormal-
ities [70, 71]. Overall, the imbalance of glutamatergic
and GABAergic signaling in FXS may represent a com-
plex interplay of abnormalities on both sides of the exci-
tatory/inhibitory neurotransmission balance.
Phenotypic rescue demonstrated in the Fmr1 KO mouse,
first with use of selective mGluR5 antagonists and later
with other mechanistic approaches, has driven the exten-
sive clinical trial work in the field since 2008. To date, a
total of 22 such studies have been identified through
search of literature and other sources; 19/22 (86%)
have been registered on www.ClinicalTrials.gov. As
expected from FXS neurobiology, the vast majority
of the studies have targeted the core excitatory/in-
hibitory imbalance in the disorder primarily through
either mGluR5 antagonists (mavoglurant-AFQ056,
NCT01357239, NCT01253629; basimglurant-RO4917523,
NCT01517698, NCT01750957) or GABA agonists (arba-
clofen-GABA-B agonist, NCT01282268, NCT00788073,
NCT01325220; ganaxolone-GABA-A agonist, NCT
01725152). These studies represent the majority of
the total (14/22, 64%) and FDA-registered (14/19,
74%) trials. Reflecting that over 2/3 of these trials
were phase II, most of them have studied adults and
adolescents (i.e., regulations specify that novel drugs
need to be tested first in adults, particularly in vul-
nerable populations). Trials of three specific mGluR5
antagonists—fenobam, mavoglurant (AFQ056), and
basimglurant (RO4917523)—in human FXS study have
been completed. The first pilot trial involved fenobam
[N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-
imidazole-2-yl)urea], a nonbenzodiazepine anxiolytic drug
and negative allosteric modulator of mGluR5 [72]. An
open-label single-dose study was conducted in 6 males
and 6 females with FXS in the 18 to 30-year-old range
[73]. This pilot study initially evaluated drug safety and
pharmacokinetics and explored aspects of sensory gating,
attention and inhibition by evaluating prepulse inhibition
(PPI) before and after each single dose fenobam treatment.
No significant adverse events were noted. Six out of 12
(50%) subjects met predefined response criterion of at
least 20% improvement over baseline on PPI at 120 ms.
Further studies in FXS were not carried out because the
company that manufactured fenobam failed financially. In
earlier reports in the general population, fenobam has
a challenging tolerability profile, with reports of hallu-
cinations, vertigo, paraesthesias, and insomnia with
fenobam use [74].
Mavoglurant is a noncompetitive mGluR5 antagonist
developed by Novartis Pharmaceuticals. Three placebo-
controlled trials of mavoglurant have been completed in
FXS. The first trial was a double-blind, placebo-
controlled 20-day treatment period crossover trial in-
cluding 30 adults with full mutation FXS [75]. While this
initial study failed to show any positive drug-associated
effect on primary or secondary outcomes, including the
Table 1 Clinical trials to date in fragile X syndrome by drug and
study type
Drug Mechanism Open Label/
Chart Review
Phase II Phase
III
Acamprosate GABA-R agonist C[98]; C[99] O
Arbaclofen GABAB-R agonist C[102] P
Basimglurant mGlur5 antagonist P
CX516 AMPAR (+)
modulator
C[85]
Donepezil Anticholinergic C[132] C[134]
Fenobam mGlur5 antagonist C[73]
Ganaxolone GABAAR agonist O
Lithium GSK3 inhibitor C[114]
Lovastatin ERK inhibitor C[125]
Mavogluranta mGlur5 antagonist C[75], C[76,
106]
D
Memantine NMDAR antagonist C[84]
Metadoxine
ER
GABA agonist P
Minocycline MMP9 inhibitor C[117] C[117]
Oxytocin OXTR agonist C[143]
Riluzole Glutamate agonist C[93]
R04917523 mGlurR5 antagonist D
Trofinetideb IGF-1 mimic P
Key: C completed and published, P completed and pending publication, O
ongoing clinical trial, www.clinicaltrials.gov, D discontinued and unpublished
aAFQ056
bNNZ-2566
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Aberrant Behavior Checklist (ABC) or Clinical Global
Impressions (CGI) scales, in the whole study group, a
post-hoc subset analysis of seven individuals with
complete FMR1 promoter methylation noted significant
drug-associated improvement on a number of behavioral
outcome measures. This post-hoc effect may have been
driven by an abnormally low placebo response in the
small seven-subject subset of patients with complete
methylation. This finding could also could be attribut-
able to regression to the mean with those with complete
methylation with a potentially more significantly im-
paired phenotype. Two additional large-scale double-
blind, placebo-controlled, parallel groups, fixed-dose
four-arm (placebo, 25 mg BID, 50 mg BID, and 100 mg
BID dosing) studies with open label extension were con-
ducted with mavoglurant in FXS [76]. The trials in-
cluded 12-week adult (age range 18–45 years) and
adolescent (age range 12–17 years) placebo-controlled
treatment periods, both utilizing the total score of a
FXS-refactored version [77] of the Aberrant Behavior
Checklist-Community (ABC-C) [78], termed ABCFX, as
a primary outcome. Neither study met significance on
the primary endpoint and the sponsor subsequently
terminated the open-label extension portion of the
studies and discontinued the development program of
mavoglurant in FXS (ClinicalTrials.gov Identifiers:
NCT01253629, NCT01357239); [76, 79].
A third selective mGluR5 antagonist, basimglurant,
was evaluated in a small phase IIa placebo-controlled
PK study in adults, a subsequently a larger phase IIb 3-
month double-blind, placebo-controlled study in adoles-
cents and adults (age range 14-50 years) (ClinicalTrials.
gov Identifier: NCT01517698), and a small phase IIa
pharmacokinetic study in youth (age range 5-13 years)
with FXS (ClinicalTrials.gov Identifiers: NCT01015430,
NCT01750957). Although all the trial results remain un-
published, due to lack of efficacy on a number of behav-
ioral and other outcome measures employed in phase IIb
adult/adolescent study, the Roche Group subsequently
terminated its program for the development of basimglur-
ant in FXS [80].
Mavoglurant and basimglurant trial results have
made it clear that short-term selective mGluR5 antag-
onism is not associated with significant behavioral im-
provement in the age ranges studied. Several questions
remain to be answered, including what impact this
class of drugs may have on very young children and
what the impact of prolonged treatment may be on
other outcomes such as cognitive or communication
metrics. The selective mGluR5 antagonist trials to date
have also been limited by the employed outcome
measures, with a focus on parent-reported behavioral
outcomes that resulted in dramatically enhanced pla-
cebo response.
In addition to evidence of mGluR5 dysregulation in
FXS, activity at the NMDA glutamate receptor may be
anomalous in the disorder, although the overall direction-
ality of dysregulation is unclear, appearing in preclinical
models to depend on brain region and developmental
stage [26, 81–83]. Memantine (3,5-dimethyladamantan-1-
amine), a compound that acts as a NMDA noncompetitive
antagonist, is the US Food and Drug Administration
(FDA) approved for the management of Alzheimer’s dis-
ease. In the only published trial of memantine in humans
(age range 13–22 years, n = 6) with FXS to date, over a
mean 34.7 weeks of open-label treatment, 4 subjects
showed clinical improvement as rated by the Clinical
Global Impression–Improvement subscale (CGI-I), but
2 subjects had to discontinue therapy due to in-
creased irritability with treatment [84]. No specific
domains of symptom or behavioral improvement were
noted and the authors cautioned about future explor-
ation of this drug given the worsening irritability
noted in one third of subjects.
AMPAR is an ionotropic glutamate receptor mediating
fast synaptic transmission. Modulation of AMPAR activ-
ity downstream of mGluR signaling, was initially pro-
posed as a method of restoring excitatory:inhibitory
signaling balance in FXS [8]. Level of internalization of
AMPARs, which is increased in the Fmr1 KO mouse,
may contribute to alterations in LTD and LTP in FXS
since AMPAR signaling is required for maintaining
synaptic plasticity. A positive allosteric modulator of
AMPAR, CX516, was tested in a 4-week double-blind,
placebo-controlled trial in FXS. The trial failed to find a
significant treatment-associated improvement in mem-
ory, the study’s primary measure, or any secondary end-
point including measures of language skills, behavior,
and global improvement. The authors hypothesized that
CX516 drug effect may have been limited by potential
subtherapeutic dosing based on information that became
available concurrent to the trial [85]. Despite the negative
study findings, the CX516 trial laid the groundwork for
the use of many outcome measures in future FXS trials by
providing invaluable data regarding which measures may
not be as affected by floor, ceiling, or test-retest inconsist-
ency effects.
Beyond drugs solely modulating glutamatergic neuro-
transmission, several agents with combined glutamate and
GABA activity have been studied in FXS. Dysregulation of
the ERK intracellular signaling pathway has been impli-
cated in the pathophysiology of FXS and as such has
become a potential target of treatment in the disorder.
Acting downstream from several cellular receptors includ-
ing mGluRs, ERK activity is required for normal synaptic
plasticity and the regulation of activity dependent protein
synthesis [86]. ERK activity has been demonstrated to be
upregulated under baseline conditions in the Fmr1 KO
Erickson et al. Journal of Neurodevelopmental Disorders  (2017) 9:7 Page 4 of 14
mouse and in human post-mortem tissue [28, 49, 87]. The
kinetics of ERK activation is delayed in FXS, potentially
because of baseline hyperactivation. Reduction of
phosphorylated (activated) ERK has been linked to
rescuing the audiogenic seizure phenotype [87] and the
increased hippocampal protein synthesis in the Fmr1
KO mouse [88].
Riluzole is FDA-approved for the treatment of amyo-
trophic lateral sclerosis (ALS) and may potentially be use-
ful in the treatment of depression and anxiety [89, 90].
The drug is hypothesized to inhibit glutamate release [91]
and potentiate post-synaptic GABA(A) receptor activity
[92]. Riluzole was the subject of a small six subject 6-week
open-label study in adult males with FXS [93]. Only 1 in 6
subjects (16%) showed a positive clinical response after
the brief treatment (100 mg/day). Despite the lack of sig-
nificant clinical effect, peripheral lymphocytic ERK activa-
tion, which is known to be delayed in blood lymphocytes
in FXS human and animal models [94], was significantly
corrected in all subjects following the 6-week riluzole
treatment. This result, potential rescue of molecular dys-
regulation combined with a lack of clinical response, may
be a signal that short-term trials are not allowing the time
for molecular change to generate resultant positive change
in the clinical phenotype of FXS. It may also be possible
that ERK dysregulation is a downstream consequence of a
different molecular mechanism and thus an isolated
correction of ERK activity could lack significant clin-
ical impact.
Acamprosate is FDA-approved for the maintenance of
abstinence in alcohol dependence. Acamprosate is hy-
pothesized to have combined effects on excitatory:inhibi-
tory balance in brain, including potential potentiation of
GABA(A) activity [95] and antagonism at mGluR5 [96]
and NMDA glutamate receptors [97]. Acamprosate has
been the subject of several open-label reports in FXS in-
cluding an initial report on 3 adults with FXS who re-
ceived a mean 21.3 weeks of acamprosate treatment
[98]. In this study, each adult showed a positive clinical
treatment response marked in part by enhancement in
language and communication skills. In the first investi-
gation of acamprosate in youth with FXS, over 10 weeks
of open-label treatment (mean dose 1054 ± 422 mg/day),
9 of 12 youths were deemed treatment responders with
response marked by a score of “much” or “very much
improved” on the CGI-I [99]. In addition, overall group
improvement was noted on the ABC-C Social With-
drawal subscale (ABC-SW), Social Responsiveness Scale
(SRS), and attention deficit hyperactivity disorder rating
scale (ADHD-RS). In this report, plasma BDNF was
sampled at baseline and after acamprosate treatment.
Acamprosate use was associated with increases in
peripheral BDNF levels after 10 weeks of treatment.
Additionally, plasma amyloid precursor protein (APP)
and APP alpha were reduced with acamprosate use in
this trial [100]. Overall, in open-label studies, acampro-
sate has shown promise to improve the clinical pheno-
type of FXS and the drug has been associated with two
aspects of molecular change that may signal aspects of
engagement with the underlying molecular dysregulation
that characterizes the disorder. Acamprosate is currently
undergoing double-blind, placebo-controlled 10-week
study in 48 persons with FXS age 5–22 years (Clinical-
Trials.gov Identifier: NCT01911455).
The neuroactive steroid ganaxolone (3a-hydroxy-3B-
methyl analog of allopregnanolone) is a positive allo-
steric modulator at GABA(A) receptors. Ganaxolone has
blocked audiogenic seizures in the Fmr1 KO mouse
[101]. A double-blind, placebo-controlled 6-week treat-
ment period, crossover trial of ganaxolone was recently
completed in 6–17 years old with FXS (ClinicalTrials.gov
Identifier: NCT01725152), although results have not yet
been published or presented. This first in FXS ganaxo-
lone study aimed to determine the safety, tolerability,
and efficacy of the drug for the treatment of anxiety and
attention deficits in FXS.
Arbaclofen, the active entaniomer of racemic baclofen,
is a GABA(B) agonist studied to date in FXS and in idio-
pathic ASD. Arbaclofen, a presynaptic GABA(B) agonist,
is postulated to inhibit glutamatergic release, thus poten-
tially limiting neuronal hyperexcitability associated with
FXS. In the Fmr1 KO mouse, arbaclofen was shown to re-
duce susceptibility to audiogenic seizures and normalize
excessive dendritic spine density and protein synthesis
[70]. In a double-blind, placebo-controlled 4-week treat-
ment period crossover trial in 63 persons with FXS age 6–
40 years, the drug was well tolerated but not associated
with a positive drug effect on the study primary outcome,
the ABC-C Irritability subscale (ABC-I) [102]. Other out-
comes, including a parent visual analog scale (VAS) of the
child’s 3 most challenging behaviors reported by care-
givers and the ABC Social Avoidance (ABC-SA) sub-
scale, which was developed specifically by re-factoring
the ABC-C in the FXS population (ABCFX) [77] were
improved on arbaclofen in the entire per intent-to-treat
(ITT) treatment group. In post-hoc analyses, a more
socially impaired subgroup defined by high ABC-C So-
cial Withdrawal (ABC-SW) scores at baseline showed a
positive drug-associated treatment effect on many
measures including the CGI-Severity (CGI-S), CGI-I,
treatment preference, VAS, and ABCFX Social Avoid-
ance subscale. Subsequent phase III studies of arbaclo-
fen in FXS across children, adolescents, and adults did
not show significant drug-associated improvement on
primary outcome measures tested (Berry-Kravis et al.
2016, companion paper in this issue of the Journal).
The pediatric study did show arbaclofen-associated
broader measures improvement on several key secondary
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outcomes and a trend toward significance for arbaclofen
on the primary endpoint, but the study was not adequately
powered for the primary outcome measure due to early
closure for financial reasons. These results combined
with parallel negative phase III findings in idiopathic
ASD led to the discontinuation of the development of
arbaclofen by Seaside Therapeutics, when the com-
pany ceased operations.
Targeted treatment development beyond
glutamate and/or GABA modulation
Metadoxine (pyridoxol l-2-pyrrolidone-5-carboxylate) has
been used to treat alcohol intoxication outside of the
USA for many years. Metadoxine ER (MDX), which
has been shown to increase striatal dopamine levels
in murine models [103], is currently being developed
by Alcobra Pharmaceuticals for use in adult and
pediatric ADHD. MDX is currently in phase III devel-
opment for adults with ADHD (ClinicalTrials.gov
Identifiers: NCT02477748 and NCT02189772). In the
Fmr1 KO mouse, as reported by Alcobra but not
available in a peer-reviewed manuscript format, MDX
use was associated with improvements in attention,
memory, learning, hyperactivity, and sociability, which
were associated withmolecular normalization of Akt
and ERK over-activity (http://www.alcobra-pharma.
com/releasedetail.cfm?ReleaseID=847048). A 6-week
randomized, double-blind, placebo-controlled trial of
MDX enrolling 62 persons (57 completed treatment) with
FXS, age 14–55 years (mean age: 24 years), was recently
completed (ClinicalTrials.gov Identifier: NCT02126995)
[104]. MDX use was not associated with significant im-
provement on the study’s primary outcome measure: the
inattentive subscale of the ADHD Rating Scale 4th Edition
(ADHD-RS-IV). An analysis of secondary outcomes
included a positive report of MDX-associated benefit as
measured by the Vineland Adaptive Behavior Scale,
Second Edition (Vineland-II) Daily Living Skills Domain
[76, 104, 105] and the computerized cognitive Test of
Attentional Performance for Children (KiTAP) Go-NoGo
subscale false reactions (p = 0.043). Although improve-
ment on the Vineland-II would be an important functional
outcome in FXS, future work including replication is ne-
cessary to further understand any potential utility of MDX
use in persons with FXS.
Lithium is an effective mood stabilizer, FDA-approved
for the treatment of bipolar disorder. The drug has com-
bined effects including inhibition of glycogen synthase
kinase-3 beta (GSK-3b). GSK-3b has been shown to be
dysregulated in the Fmr1 KO mouse [106, 107]. In this
model of FXS, lithium use has been associated with im-
provements in hyperactivity, social preference, learning,
and aberrant dendritic spine development [108]. Lithium
has also been shown to rescue synaptic plasticity, protein
synthesis, and aberrant GSK-3b activity in the Fmr1 KO
mouse [109–112]. Lithium has been evaluated in a 15-
person open-label 2-month study in FXS [113]. In this
report, lithium use was not associated with significant
improvement on the ABC-I, but did show treatment-
associated improvement on a number of secondary out-
come measures including other ABC-C subscales, the
ABC-C total score, the CGI-I, a visual analog scale
(VAS) for behavior, the Repeatable Battery for the
Assessment of Neuropsychological Status (RBANS) List
Learning subtest assessing verbal memory, and ERK acti-
vation in lymphocytes. Adverse effects associated with
lithium use in this trial included aggression, polydipsia,
and enuresis. The side effect profile of lithium including
risk of thyroid and renal impairment has limited further
development of this compound in FXS.
Minocycline, an FDA-approved antibiotic treatment
for acne in youth, is known to have inhibitory effects on
MMP-9 activity. MMP-9 activity has been demonstrated
to be elevated in the hippocampus of Fmr1 KO mice
[114]. In this mouse model of FXS, minocycline treat-
ment was associated with reduced hyperactivity and im-
provement in dendritic spine phenotype [115]. In an
initial 8-week open-label minocycline trial in 20 persons
with FXS age 13 to 35 years, the drug treatment was as-
sociated with widespread improvement as captured by
the CGI and ABC subscales [116]. A subsequent 12-
week treatment period double-blind, placebo-controlled
crossover trial in 55 subjects age 3.5 to 16 years with
FXS noted drug-associated improvement on the CGI-I,
but no group-wide improvement in specific behavioral
domains [117]. A post-hoc analysis noted improvement
on the VAS specific to anxiety and mood-related con-
cerns. In an electrophysiology analysis of a 12-subject
subgroup from the placebo-controlled minocycline trial,
minocycline use was associated with improvement in ha-
bituation to auditory stimuli as shown by an event-related
potentials (ERP) passive auditory oddball paradigm [118].
The authors hypothesized that this electrophysiological
improvement in habituation may be related to improve-
ments in hypersensitivity to auditory stimuli noted in
humans with FXS following minocycline administration.
Dziembowska et al. (2013) demonstrated that MMP-9
blood level was significantly elevated in 20 patients with
FXS compared to controls; 6 of the 10 children treated
with minocycline for 12 weeks showed a significant lower-
ing of their MMP-9 levels, although their response on the
CGI-I did not correlate with the degree of MMP-9 lower-
ing. Although minocycline is recognized primarily for low-
ering MMP-9, it has multiple other effects including
stalling translation, decreasing apoptosis, and working as
an antioxidant, all of which may be helpful in FXS [119].
Lovastatin is a compound FDA-approved for the long-
term management of familial hyper-cholesterolemia
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[120], with demonstrated effects on intracellular signal-
ing. In cultured rat brain neuroblasts, lovastatin was
shown to inhibit Ras signaling, an upstream effect that
resulted in reduction in ERK activation [121] that sup-
ported previous work in fibroblasts [122]. In Fmr1 KO
mice, lovastatin was confirmed to inhibit Ras, reduce in-
creased basal ERK activation, lower protein synthesis to
wild type levels, and ameliorate FXS audiogenic seizure
susceptibility [123]. Based upon the known safety profile
of lovastatin and the aforementioned promising preclin-
ical results, efficacy of lovastatin in FXS was assessed in
a 16-person, open-label trial of children and adolescents.
Treatment response was assessed using the ABC-C,
CGI-I, and Vineland-II. Significant improvement was
observed after 4 and 12 weeks of treatment, with the
ABC-C, CGI, and Vineland-II scores improving from
week 4 to week 12. Excessive ERK activity measured in
platelets was reduced by lovastatin in this trial and cor-
related with behavioral improvement on the ABC-C.
There was modest improvement on the CGI-I, but the
open-label nature of the trial precludes any strong infer-
ences of efficacy at this stage of development [124]. Fur-
thermore, particular importance should be placed on
lipid monitoring in future lovastatin trials since individ-
uals with FXS were reported to have lower levels of low
and high density lipoprotein and total cholesterol [125].
A synthetic analog of the naturally occurring active N-
terminal tripeptide derived of the insulin-like growth fac-
tor 1 (IGF-1), known as NNZ-2566 or trofinetide has been
studied in the Fmr1 KO mouse and in humans with FXS.
The drug was initially developed for traumatic brain in-
jury, where trofinetide showed promise with improved re-
covery, reduction in apoptotic cell death, and reduced
neuroinflamation noted in a rat model [126–128]. In the
Fmr1 KO mouse, trofinetide has been reported to rescue
learning and memory deficits, normalize dendritic spine
morphology, and restore normal ERK signaling [129].
Recently, a double-blind, placebo-controlled 4-week trial
of NNZ-2566 in 12 to 45 year old males with FXS was
completed. The study used both parent- and clinician-
reported outcomes designed to address the entire FXS
phenotype, including an FXS Rating Scale and FXS
Domain Specific Concerns measure. A composite
analysis of five measures from three domains utilized
a novel direction of clinical change analysis plan, in-
cluding a group and individual analyses. Both clini-
cians and caregivers observed a pattern of consistent
improvements in FXS-specific measures and the ABC
total score, but only at the higher dose (70 mg/kg
b.i.d.; p = 0.045 by premutation testing) (p = 0.045 by
permutation testing) (ClinicalTrials.gov Identifier:
NCT01894958). Considering similar positive results
in a comparable trial of adolescents and adults with
Rett syndrome, trofinetide appears to be a promising
drug for neurodevelopmental disorders (ClinicalTrials.gov
Identifier: NCT01703533).
Given reports of altered choline levels and cholinergic
function in FXS murine models and in human studies,
donepezil, an acetylcholinesterase inhibitor FDA-approved
for the treatment of Alzheimer’s disease, has been initially
investigated in FXS. Specifically, FMR1 has been shown to
be highly expressed in cholinergic neurons during the
course of normal development [130], and choline levels
were shown to be lower in persons with FXS in a small
1H magnetic resonance spectroscopy study [131]. Add-
itionally, dysregulated cholinergic function has also been
demonstrated in the subiculum of Fmr1 KO mice [132].
In humans with FXS, a 9-subject, 6-week open-label trial
of donepezil reported good drug tolerability and signifi-
cant treatment-associated improvement on the ABC-C
Hyperactivity and Irritability subscales [131]. Recently, re-
sults from a 12-week randomized double-blind, placebo-
controlled trial of donepezil (maximum dose 5 mg per
day) in 20 boys (mean age 9.1 ± 2.6 years) with full muta-
tion FXS have been reported [133]. In this study, donepe-
zil use was not associated with significant positive change
on outcome measures employed including the Stanford-
Binet Intelligence Scale, Conners 3 parent ADHD rating
scale, or the Childhood Autism Rating Scale (CARS).
Researchers at Stanford University recently completed a
12-week randomized double-blind, placebo-controlled,
parallel-group study of donepezil (dosed 2.5 to 10 mg per
day) in 42 persons with FXS (27 males, 15 females; enrol-
ling both youth and adults under age 65) (ClinicalTrials.
gov Identifier: NCT01120626), using the Contingency
Naming Test (CNT) as the primary outcome measure.
Analyzed results from this project are not yet available.
Sertraline, an SSRI, is known to improve BDNF levels in
the CNS and to boost the deficient serotonin levels seen on
positron emission tomography (PET) scanning in the brains
of children with ASD who are under 5 years old [134, 135].
A randomized controlled trial of low-dose sertraline (2.5 to
5.0 mg) for 6 months in 57 young children ages 2 to 6 years
with FXS was recently carried out (Greiss-Hess et al. 2016,
JDBP, in press). Significant improvements were not shown
on the primary outcome measures—the CGI-I and the ex-
pressive language subtest on the Mullen Scales of Early
Learning (MSEL). However, subjects did demonstrate sig-
nificant improvement on the Visual Perception subscale,
Fine Motor subscale, and composite T score of the MSEL
in secondary analyses. In addition, in a post-hoc analysis
those children with comorbid FXS and ASD (60% of
sample) demonstrated significant improvement on the
Expressive Language subscale of the MSEL.
Discussion
Despite a large number of positive preclinical drug stud-
ies in animal models of FXS, to date no approved FXS-
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specific drug treatments have been developed. Therefore,
the treatment of FXS (mainly behavioral abnormalities)
continues to be symptomatic. The numerous trial fail-
ures in the last decade could be attributed to a variety of
factors; prominently trial design and outcome measures.
Nevertheless, several promising areas of translational
treatment and strategies to develop such treatments in
FXS remain. Success in this field will be predicated in
part by learning from past challenges [136, 137].
During the recent phase of significant translational re-
search development in FXS, early failures may have been
in part due to attempts to pattern FXS clinical trials
after work on the FDA-approved atypical antipsychotics,
aripiprazole and risperidone, for targeting irritability (ag-
gression, self-injury, and severe tantrums) in youth with
ASD. This approach was likely influenced by advice from
regulatory bodies such as the FDA and others in indus-
try, whose experience with neurodevelopmental disabil-
ity drug approvals was limited and anchored specifically
on the use of the ABC-C to measure irritability in regis-
tration trials. Earlier on during the development of arba-
clofen for FXS, it became clear that irritability may not
be the most sensitive or specific metric by which to
judge FXS-specific treatments in development. This
early reliance on precedents in ASD irritability-focused
drug development was also likely driven by the lack of
FXS-specific outcome measures. As discussed in detail
in another article in this issue, the FXS field has been
spending considerable efforts to develop novel and bet-
ter outcome measures, but to date such instruments are
not in regular use. The emphasis on using the ABC-C
because it was previously vetted by the FDA may have
focused trials on a behavioral irritability, a potentially
less marked clinical manifestation in FXS when com-
pared to ASD. Moreover, this focus also likely led to use
of the ABC-C total score (combination of all ABC-C
subscales’ scores) as an outcome, which is not a recom-
mended or empirically supported use of the measure
because a subject may have a mix of worsening and
improvement in various behavioral aspects evaluated by
different ABC-C subscales, thus blurring interpretation
of a “total” score.
The FXS clinical trial field developed quickly marked
by the need for a multi-site trial infrastructure where
none previously existed. Within the last decade, industry
rapidly developed molecules for large-scale placebo-
controlled study in FXS. The rapid rate of clinical trials
developed in FXS may have contributed to some early
multi-site trial challenges. Issues such as across-site rat-
ing and assessment of enrollment criteria fidelity may
have presented challenges to consistent study ratings.
For example, in a study of arbaclofen in idiopathic ASD,
a result was reported on the Vineland-II for only sub-
jects assessed per protocol with a description of how
many subjects did have the Vineland-II administered as
requested. Such a finding may point to how having a
more established multi-site trial infrastructure over time
may improve study fidelity. Fortunately, developments
such as the Fragile X Clinical and Research Consortium
by the National Fragile X Foundation and enhanced site
training over time has led to establishment of a trial in-
frastructure prepared to generate the most accurate and
consistent trial data possible.
One important concern about the progression of the
translational effort in FXS is the reliance on post-hoc
analyses of preliminary studies in making critical subse-
quent clinical trial study design decisions for larger,
more pivotal studies examining efficacy. For example, in
the first AFQ056 clinical trial, a post-hoc analysis
showed significant improvement in just 7 subjects with
complete methylation, leading to a very substantial effort
to stratify by this variable in a much larger trial. In the
earlier arbaclofen trial, a post-hoc analysis showed im-
provement in the social avoidance subscale of the ABC
[102], leading to the decision to focus on social avoid-
ance as the primary outcome in a subsequent trial
[Berry-Kravis et al.; companion paper in this journal]. In
the metadoxine study, which focused on ADHD symp-
toms as the primary target, post-hoc analyses showed
significant improvement in daily living skills, which may
lead to decisions on the target for future study of this
compound. It may be quite rational to design future
studies based on post-hoc observations, as these adjust-
ments may lead to demonstration of the true benefits of
a compound on a different clinical problem or subgroup.
However, investigators must also appreciate the risks in
moving a focus of research in a new direction that is
based on type II error occurring when a large number of
post-hoc analyses are completed yielding one or more
“false positives”. In this regard, it may be useful to con-
sider whether several independent pieces of data suggest
a similar clinical benefit, whether the post-hoc results
represent clinically meaningful, not just statistically sig-
nificant changes, whether the changes could be more as-
sociated with side effects of the drug rather than true
improvement, and whether the clinical changes make
sense based on the understanding of the neurobiological
and pharmacological mechanisms of the compound
under investigation.
Enhanced placebo response rates have also potentially
contributed to early failures in FXS-specific treatment de-
velopment. In ASD, registration trials for risperidone and
aripiprazole targeting irritability reported placebo re-
sponse rates in the range of 12–14% [138, 139]. In FXS,
we have seen a much higher rate of placebo responder-
s—as high as 34.6% in the arbaclofen trial—that increased
the necessary treatment effect for detecting statistically
significant changes [76, 102]. This issue may be driven by
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several factors. First, there has been great anticipation
among FXS stakeholders that new treatments were on the
horizon and would build from positive drug treatment
data in FXS animal models. Developments like the mGluR
theory of FXS received significant worldwide scientific at-
tention and coverage in the general press, thus potentially
enhancing the perception that new FXS-specific treat-
ments being studied would be met with significant and
brisk success. To date, attempts at reducing placebo effect,
such as single-blind run-in treatment periods used in
study of AFQ056 (mavoglurant) have had limited benefit
in the field. Recent efforts to use more clinician-anchored
measures performed by clinician interview show promise
to reduce reliance on single parent-report measures,
which may be more prone to enhanced placebo effect. For
example, one effort by Neuren Pharmaceuticals focused
on assessing group and individual analyses for direction of
change in a diverse basket of outcomes, including both
parent and clinician report. This kind of analysis is also
more likely to assess changes impacting any aspect of the
FXS phenotype rather than just a single behavior. As the
FXS field tests treatments targeting general mechanisms,
it is expected that it will be important to evaluate the en-
tire phenotype since the degree of behavioral manifesta-
tions in different domains vary across patients. In this
regard, the further development and full validation of a
disease-specific outcome measure, such as the Fragile X
Syndrome Rating Scale (FXSRS) used in the trofinetide
trial, becomes a milestone in the process of creating better
instruments for intervention studies in FXS. There is in-
creasing evidence that individual behavioral problems in
FXS may appear differently by their co-occurrence with
others (e.g., anxiety and ASD) [140, 141]. In this regard,
the development of a comprehensive FXS behavioral
phenotype measure such as the FXSRS represents an
important effort in this area. Objective measures, either
performance-based measures of cognition or biomarkers
(discussed below) may also be used to more accurately
track treatment response with much less concern about
placebo response.
There have likely been shortcomings in attempts to
match outcome measures in FXS clinical trials to what
may be expected from short-term treatment with drugs
that rescue synaptic and other cellular pathology in mouse
models of FXS. There are no clear correlates between out-
comes employed in FXS animal studies and outcomes
employed in initial human FXS clinical trials. For example,
a drug may correct protein synthesis, dendritic spine
morphology, learning, and audiogenic seizure deficits in
the Fmr1 KO mouse. Then, when moved into human
studies, outcomes have included parent-report checklists
focused on interfering behavior, mood, anxiety, inatten-
tion, and adaptive behavior. Thus, it is unclear what type
of behavioral change would be expected with a new
treatment that rescues brain connectivity, protein synthe-
sis, and/or neuronal circuit excitability among other fea-
tures targeted in Fmr1 KO animal studies. Given this, it
will be important for the field to attempt to develop test-
ing paradigms, particularly in rodent FXS models that can
be recapitulated in FXS human studies as much as pos-
sible. Despite this, and considering that species differences
in FMRP and other regulatory proteins (e.g., MeCP2) exist
and influence brain connectivity, it is expected that only a
few phenotypes and paradigms could be applied in both
rodents and humans.
The FXS translational treatment field, like most other
similar fields attempting to bring treatments from bench
to bedside, has not developed a sense of what age range is
most appropriate to enhance chances of treatment suc-
cess. While efforts in the Fmr1 KO mouse have demon-
strated phenotypic improvement in adult animals, it is
possible that initial negative trial results in humans utiliz-
ing drugs with marked success in animal models of FXS
may be due to missing appropriate developmental win-
dows in the human FXS condition that best respond to
treatment. This thinking has led to the concept that the
earlier in life treatment is initiated, the better the chance
may be of success; this has led to the upcoming study of
mavoglurant in toddlers with FXS. Additionally, the dur-
ation of treatment necessary to enact a significant change
in humans with FXS is not known. While improvement in
behavioral and other neurobiological phenomena has oc-
curred rapidly in FXS animal models, it is unclear if
change in affected humans may take significantly longer
than the short-term trial efforts to date. Longer trials have
been inhibited by increased expense and other logistical
issues, and by a lack of available natural history data in the
field, which would allow for detection of subtle yet
potentially meaningful developmental changes over time.
There is also a potential that an effective FXS-specific
drug treatment would enact improvements in neurobio-
logical parameters that may actually enhance learning over
time as a primary readout versus quickly providing behav-
ioral symptomatic relief. If true, it will likely be necessary
to pair new treatments with structured training/learning
paradigms in order to provide standard didactic methods
to a brain that has enhanced capacity to learn (synaptic
plasticity) under the influence of a beneficial drug. Such
efforts are ongoing in the novel, recently funded trial of
mavoglurant in toddlers with FXS, where drug or placebo
will be paired with a structured, standardized language-
learning paradigm. Finally, extrapolations from genetically
homogenous inbred mice raised in controlled settings are
inherently difficult to apply to humans who, despite shar-
ing a single gene disorder, have different genetic back-
grounds and environmental exposures.
As a single gene cause of developmental disability
with increasingly well-understood neurobiology, FXS
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has been viewed as a disorder with relative homogen-
eity in particular in comparison to idiopathic ASD.
This led to the idea that it would be easier to find
consistent druggable targets in FXS whose modulation
is associated with significant symptomatic improve-
ment across a broad section of persons with the
disorder compared to treatment development in
behaviorally defined, etiologically diverse syndromes.
Several factors have eroded the simplicity and accur-
acy of this approach. As trials have occurred in FXS,
it has been clear that significant phenotypical differ-
ences exist in enrollees. This has likely led to several
post-hoc comparison approaches looking at various
subgroups, such as those with significant social with-
drawal, ASD, or anxiety. Despite being caused by dys-
functional expression of a single gene, FXS presents
with real heterogeneity, including such features as
presence or absence of spoken language, comorbid
ASD, epilepsy, significant ADHD symptoms, and,
while anxiety is one of the most consistent features of
the syndrome at least in males, the severity of anxiety
may significantly differ between patients. This vari-
ability even within just the male FMR1 full mutation
population clearly confounds study development and
outcome assessment. This is not to mention the sig-
nificant variation between the presentation of FXS in
males versus females and highly variable presentation
within females alone given their random X chromo-
some inactivation patterns. Because of this variability
of presentation, it is critical to find unifying features
of the disorder that are readily and reproducibly mea-
sured. Thus, efforts to address this variability using
quantitative biological or bio-behavioral parameters
(i.e. biomarkers) through molecular blood assays, eye
tracking technologies, or electrophysiology will be im-
portant to the field. These measures will in time need
to be correlated with clinical measures to show rele-
vance to daily functioning. Hopefully, these quantita-
tive measures can define subgroups of individuals
with consistent biological abnormalities correlated
with some clinical measure, or alternatively prove
useful in more directly tracking drug effects on func-
tional brain systems. Such work would not only allow
for potentially more effective outcome measures, but
also will provide opportunity to identify at baseline
certain persons with FXS who may best respond to a
particular treatment. It is clear that parsing the het-
erogeneity of even a single gene disorder will likely
be essential to future treatment development efforts.
As a protein responsible for translational regulation of
hundreds of other proteins throughout the brain, FMRP
has wide-reaching impact that likely cannot be con-
strained to a pathogenicity focused on a single neuro-
transmitter or other single-pharmacological approaches.
The complex sequelae of deficient FMRP represent a diverse
set of known and likely many still unidentified molecular
systems set into cellular dysregulation. This complexity may
well render single drug approaches ineffective in the dis-
order. It is quite possible that combined pharmacotherapy
approaches targeting a number of molecular or neural sys-
tems, all in a state of dysregulation, may be necessary to ren-
der significant clinical improvement in humans with FXS.
Such approaches may mirror efforts in human immunodefi-
ciency virus (HIV) and oncology work where combined
treatments may be required to address disease.
Despite the many challenges facing the FXS transla-
tional drug development field, there are many recent de-
velopments that portend potential enhancement of future
success. These include recent reports from Neuren Phar-
maceuticals describing a positive phase II study result with
trofinetide in older cohorts (adolescents and adults) with
FXS, using a novel outcome measure analysis strategy that
addresses the entire phenotype. Ongoing work to quantify
EEG abnormalities across humans with FXS and the Fmr1
KO mouse are underway in an attempt to bridge the
translation treatment gap, thus enhancing the ability to
predict [142] and monitor treatment response across spe-
cies. Given that cognitive dysfunction is ubiquitous in
FXS, treatments targeting the cognitive phenotype of the
disease and development or validation of cognitive out-
come measures are also important new directions for
research. The FXS clinical trial field has undergone signifi-
cant growth and development in recent years, thus creat-
ing a solid foundation to enhance trial fidelity across
many locations. Investigators are using new models such
as human induced pluripotent stem cell (iPSC) technology
to develop new bench treatment assays that may aid in
determining fundamental neuronal deficits in human
FXS-derived cells and potentially better replicate path-
ology germane to the human FXS condition.
Conclusions
Overall, the significant wave of FXS translational drug
treatment development in the last decade has been
marked with select improvement in FXS preclinical
models that has not yet been extrapolated to human trial
breakthroughs. Learning from the lessons of this experi-
ence will position the field well to move forward and en-
hance the opportunity for future success.
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